Marker Therapeutics, Inc.MRKRNASDAQ
LOADING
|||
Switch Symbol:
Year-over-year research & development expense growth
| Period | Value |
|---|---|
| Q3 2025 | -43.84% |
| Q2 2025 | 33.22% |
| Q1 2025 | -38.35% |
| Q4 2024 | 46.53% |
| Q3 2024 | 48.62% |
| Q2 2024 | -9.30% |
| Q1 2024 | -1.62% |
| Q4 2023 | 27.99% |
| Q3 2023 | -14.00% |
| Q2 2023 | -29.57% |
| Q1 2023 | 54.72% |
| Q4 2022 | -39.24% |
| Q3 2022 | 22.85% |
| Q2 2022 | -58.39% |
| Q1 2022 | -12.37% |
| Q4 2021 | 18.17% |
| Q3 2021 | -7.70% |
| Q2 2021 | 30.25% |
| Q1 2021 | -5.69% |
| Q4 2020 | 24.56% |
| Q3 2020 | 12.31% |
| Q2 2020 | 12.06% |
| Q1 2020 | 4.25% |
| Q4 2019 | 17.38% |
| Q3 2019 | -1.05% |
| Q2 2019 | 11.26% |
| Q1 2019 | -97.61% |
| Q4 2018 | 6223.60% |
| Q3 2018 | 2.74% |
| Q2 2018 | 14.19% |
| Q1 2018 | 11.42% |
| Q4 2017 | -11.52% |
| Q3 2017 | 34.91% |
| Q2 2017 | 21.63% |
| Q1 2017 | 116.53% |
| Q4 2016 | -58.81% |
| Q3 2016 | -11.14% |
| Q2 2016 | 26.60% |
| Q1 2016 | 650.06% |
| Q4 2015 | -82.91% |